Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCS-2 extension in BPH/LUTS
NCT01002274Phase 3Completed
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
- Start
- Aug 2010
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of MCS-2 in benign prostatic hyperplasia (BPH), lower urinary tract symptoms (LUTS), sponsored by Health Ever Bio-Tech Co., Ltd.. Started Aug 2010; status: completed.
02
Drugs
MCS-2
03
Conditions
benign prostatic hyperplasia (BPH)lower urinary tract symptoms (LUTS)
Beyond the preview
Go deeper on NCT01002274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01002274.